Advantages of TRUS-based delineation for high-dose-rate prostate brachytherapy planning

被引:4
|
作者
Lavoie-Gagnon, Heloise [1 ]
Martin, Andre-Guy [1 ,2 ]
Poulin, Eric [1 ]
Archambault, Louis [1 ,2 ]
Pilote, Laurie [3 ]
Foster, William [1 ]
Vigneault, Eric [1 ,2 ]
Carignan, Damien [1 ,2 ]
Lacroix, Frederic [1 ]
机构
[1] Univ Laval, CHU Quebec, Dept RadioOncol, 11 Cote Palais, Laval, PQ, Canada
[2] Univ Laval, CHU Quebec, Ctr Rech, Laval, PQ, Canada
[3] Hotel Dieu Levis, Dept RadioOncol, Levis, PQ, Canada
关键词
brachytherapy; prostate cancer; delineation; registration; ultrasound; high-dose-rate; MAGNETIC-RESONANCE; RADICAL PROSTATECTOMY; PENILE STRUCTURES; VOLUME; CT; MONOTHERAPY; RISK; MRI; UNCERTAINTIES; INTERMEDIATE;
D O I
10.5114/jcb.2022.113544
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the variability of prostate contours delineated on computed tomography (CT) and transrectal ultrasound (TRUS). Material and methods: A TRUS-based high-dose-rate (HDR) brachytherapy procedure was introduced in 2016 in our center. The first thirty patients were additionally imaged with CT immediately after the treatment. In 2018, four different radiation oncologists (ROs: 1, 2, 3, 4) contoured the prostate on both modalities. A volume comparison was performed between CT and TRUS imaging. Using prostate gold fiducial makers, a rigid registration between CT and TRUS was done in 20 of the 30 patients studied. Jaccard index (JI) was computed to evaluate the inter-observer volume delineation agreement. Results: The ratio of TRUS/CT volumes was 0.82 (95% CI: 0.79-0.87%). The mean JI was 87% for CT and 92% for TRUS, when comparing all four ROs; CT and TRUS JIs were significantly different (p < 0.001). The mean JI for the pros- tate on CT was significantly more consistent (p < 0.001) when comparing RO1, 2, and 3 together (RO1-2, RO1-3, and RO2-3; mean = 89%) than when comparing RO4 (newest to clinical practice) to others (RO1-4, RO2-4, and RO3-4; mean = 85%). For TRUS planning, the mean JI was not significantly different (p > 0.05) when comparing all ROs. Conclusions: The inter-observer and intra-observer variability were statistically significantly smaller on TRUS compared to CT-based planning, despite varying ROs clinical experiences. The superior soft tissue contrast offered by TRUS obviates the effect of the ROs experience on prostate contour volumes and enables more reproducible prostate delineation.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [31] High-dose-rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome
    Strouthos, Iosif
    Karagiannis, Efstratios
    Zamboglou, Nikolaos
    Ferentinos, Konstantinos
    CANCER REPORTS, 2022, 5 (01)
  • [32] A comparison of anatomy-based inverse planning with simulated annealing and graphical optimization for high-dose-rate prostate brachytherapy
    Morton, Gerard C.
    Sankreacha, Raxa
    Halina, Patrick
    Loblaw, Andrew
    BRACHYTHERAPY, 2008, 7 (01) : 12 - 16
  • [33] High-dose-rate brachytherapy as monotherapy for prostate cancer: 5-year results
    Solodkiy, V. A.
    Pavlov, A. Yu
    Tsybulskii, A. D.
    Dzidzaria, A. G.
    Sorokin, A. S.
    Mirzakhanov, R., I
    ONKOUROLOGIYA, 2022, 18 (01): : 58 - 69
  • [34] High-Dose-Rate Brachytherapy Boost to the Dominant Intra-Prostatic Tumor Region: Hemi-Irradiation of Prostate Cancer
    Schick, Ulrike
    Popowski, Youri
    Nouet, Philippe
    Bieri, Sabine
    Rouzaud, Michel
    Khan, Haleem
    Weber, Damien Charles
    Miralbell, Raymond
    PROSTATE, 2011, 71 (12) : 1309 - 1316
  • [35] The Influence of Prostate Volume on Outcome After High-Dose-Rate Brachytherapy Alone for Localized Prostate Cancer
    Le, Hien
    Rojas, Ana
    Alonzi, Roberto
    Hughes, Robert
    Ostler, Peter
    Lowe, Gerry
    Bryant, Linda
    Hoskin, Peter
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : 270 - 274
  • [36] Dosimetry modeling for focal high-dose-rate prostate brachytherapy
    Mason, Josh
    Al-Qaisieh, Bashar
    Bownes, Peter
    Thwaites, David
    Henry, Ann
    BRACHYTHERAPY, 2014, 13 (06) : 611 - 617
  • [37] Salvage high-dose-rate brachytherapy for recurrent prostate cancer
    Kaprin, A. D.
    Ivanov, S. A.
    Karyakin, O. B.
    Obuhov, A. A.
    Biryukov, V. A.
    Borysheva, N. B.
    Sanin, D. B.
    Lepilina, O. G.
    Smolkin, A. L.
    Dem'yanovich, A., V
    Minaeva, N. G.
    Mikhaylovskiy, N., V
    ONKOUROLOGIYA, 2020, 16 (04): : 112 - 119
  • [38] Open MR-Guided High-Dose-Rate (HDR) Prostate Brachytherapy: Feasibility and Initial Experiences Open MR-Guided High-Dose-Rate (HDR) Prostate Brachytherapy
    Lakosi, Ferenc
    Antal, Gergely
    Vandulek, Csaba
    Kovacs, Arpad
    Toller, Gabor L.
    Rakasz, Istvan
    Bajzik, Gabor
    Hadjiev, Janaki
    Bogner, Peter
    Repa, Imre
    PATHOLOGY & ONCOLOGY RESEARCH, 2011, 17 (02) : 315 - 324
  • [39] High-dose-rate brachytherapy as a monotherapy for prostate cancer-Single-institution results of the extreme fractionation regimen
    Kukielkal, Andrzej Marek
    Dabrowski, Tomasz
    Walasek, Tomasz
    Olchawa, Agnieszka
    Kudzia, Roksana
    Dybek, Dorota
    BRACHYTHERAPY, 2015, 14 (03) : 359 - 365
  • [40] American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy
    Yamada, Yoshiya
    Rogers, Leland
    Demanes, D. Jeffrey
    Morton, Gerard
    Prestidges, Bradley R.
    Pouliot, Jean
    Cohen, Gil'ad N.
    Zaider, Marco
    Ghilezan, Mihai
    Hsu, I-Chow
    BRACHYTHERAPY, 2012, 11 (01) : 20 - 32